Publication
Title
Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency
Author
Abstract
Endothelial cells (ECs) secrete different paracrine signals that modulate the function of adjacent cells; two examples of these paracrine signals are nitric oxide (NO) and neuregulin-1 (NRG1), a cardioprotective growth factor. Currently, it is undetermined whether one paracrine factor can compensate for the loss of another. Herein, we hypothesized that NRG1 can compensate for endothelial NO synthase (eNOS) deficiency. We characterized eNOS null and wild-type (WT) mice by cardiac ultrasound and histology and we determined circulating NRG1 levels. In a separate experiment, eight groups of mice were divided into four groups of eNOS null mice and WT mice; half of the mice received angiotensin II (ANG II) to induce a more severe phenotype. Mice were randomized to daily injections with NRG1 or vehicle for 28 days. eNOS deficiency increased NRG1 plasma levels, indicating that ECs increase their NRG1 expression when NO production is deleted. eNOS deficiency also increased blood pressure, lowered heart rate, induced cardiac fibrosis, and affected diastolic function. In eNOS null mice, ANG II administration not only increased cardiac fibrosis but also induced cardiac hypertrophy and renal fibrosis. NRG1 administration prevented cardiac and renal hypertrophy and fibrosis caused by ANG II infusion and eNOS deficiency. Moreover, Nrg1 expression in the myocardium is shown to be regulated by miR-134. This study indicates that administration of endothelium-derived NRG1 can compensate for eNOS deficiency in the heart and kidneys. NEW & NOTEWORTHY ECs compensate for eNOS deficiency by increasing the secretion of NRG1. NRG1 administration prevents cardiac and renal hypertrophy and fibrosis caused by ANG II infusion and eNOS deficiency. NRG1 expression is regulated by miR-134.
Language
English
Source (journal)
American journal of physiology : heart and circulatory physiology / American Physiological Society. - Bethesda, Md, 1977, currens
Publication
Bethesda, Md : 2021
ISSN
0363-6135 [print]
0363-6135
1522-1539 [online]
DOI
10.1152/AJPHEART.00914.2020
Volume/pages
320 :6 (2021) , p. H2416-H2428
ISI
000661571800020
Pubmed ID
33989083
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Project info
Activating the neuregulin-1/ErbB4 pathway for treatment of heart failure.
Studies of the ErbB4 receptor in myocardial non-myocytes to create new opportunities for the treatment of cardiac disease.
Development of ErbB4 Agonists for Treatment of Heart Failure.
Infla-Med: Fundamental and translational research into targets for the treatment of inflammatory diseases.
Identification of small molecule ErbB4 agonist for treatment of heart failure, diabetic kidney injury and fibrotic disorders.
Defining atrial myopathy in aging and disease (DIAMOND consortium).
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 30.07.2021
Last edited 25.12.2024
To cite this reference